|
KMID : 0620920130450020003
|
|
Experimental & Molecular Medicine
2013 Volume.45 No. 2 p.3 ~ p.0
|
|
|
Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells
|
|
Park Sung-Nam
Noh Kyung-Tae
Jeong Young-Il
Jung In-Duk
Kang Hyun-Kyu
Cha Gil-Sun
Lee Su-Jung
Seo Jong-Keun
Kang Dae-Hwan
Hwang Tae-Ho
Lee Eun-Kyung
Kwon Byung-Suk
Park Yeong-Min
|
|
|
Abstract
|
|
|
|
We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1β, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8+ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.
|
|
|
KEYWORD
|
|
|
adjuvant, dendritic cells, rhamnogalacturonan II, Toll-like receptor 4, tumor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|